Story excerpt provided by The Plain Dealer.
Written by Robert L. Smith.
BioMotiv, a drug discovery company associated with University Hospitals, announced Thursday it has attracted a $25 million investment from Japan’s largest drug maker.
Takeda Pharmaceutical of Osaka will buy a minority stake in BioMotiv in exchange for exclusive access to its drugs that show promise treating cardio-metabolic diseases, like diabetes and heart disease, as well as diseases associated with immunology and inflammation.
Click here to read the complete article.
Originally published September 25, 2014.